David Chandiwana

561 total citations
49 papers, 382 citations indexed

About

David Chandiwana is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, David Chandiwana has authored 49 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Pulmonary and Respiratory Medicine, 29 papers in Oncology and 7 papers in Genetics. Recurrent topics in David Chandiwana's work include Advanced Breast Cancer Therapies (40 papers), HER2/EGFR in Cancer Research (18 papers) and Cancer Treatment and Pharmacology (15 papers). David Chandiwana is often cited by papers focused on Advanced Breast Cancer Therapies (40 papers), HER2/EGFR in Cancer Research (18 papers) and Cancer Treatment and Pharmacology (15 papers). David Chandiwana collaborates with scholars based in United States, Germany and Canada. David Chandiwana's co-authors include Anand A. Dalal, Jinhee Park, Thomas E. Delea, Emilio Alba, Wolfgang Janni, Sunil Verma, Mario Campone, Joyce O’Shaughnessy, Santosh Sutradhar and Howard A. Burris and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

David Chandiwana

45 papers receiving 376 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Chandiwana United States	12	278	231	111	80	43	49	382
Mark L. Zangardi United States	7	240 0.9×	242 1.0×	68 0.6×	87 1.1×	45 1.0×	14	396
Gregory L. Price United States	12	301 1.1×	313 1.4×	95 0.9×	160 2.0×	90 2.1×	30	527
S. Stein United States	10	102 0.4×	306 1.3×	73 0.7×	59 0.7×	77 1.8×	15	448
Yong Mun United States	11	115 0.4×	313 1.4×	32 0.3×	54 0.7×	132 3.1×	43	464
O. Rixe France	8	128 0.5×	355 1.5×	170 1.5×	18 0.2×	89 2.1×	16	482
Joanne Cox United States	6	525 1.9×	430 1.9×	170 1.5×	214 2.7×	32 0.7×	13	638
B. Newstat United Kingdom	7	175 0.6×	460 2.0×	74 0.7×	88 1.1×	70 1.6×	14	516
Natascha A. J. B. Peters Netherlands	8	310 1.1×	392 1.7×	263 2.4×	27 0.3×	64 1.5×	20	547
Tristan Maurina France	10	154 0.6×	108 0.5×	73 0.7×	18 0.2×	118 2.7×	30	293
Guilherme Harada Brazil	11	161 0.6×	155 0.7×	66 0.6×	14 0.2×	90 2.1×	40	317

Countries citing papers authored by David Chandiwana

Since Specialization

Citations

This map shows the geographic impact of David Chandiwana's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Chandiwana with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Chandiwana more than expected).

Fields of papers citing papers by David Chandiwana

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Chandiwana. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Chandiwana. The network helps show where David Chandiwana may publish in the future.

Co-authorship network of co-authors of David Chandiwana

This figure shows the co-authorship network connecting the top 25 collaborators of David Chandiwana. A scholar is included among the top collaborators of David Chandiwana based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Chandiwana. David Chandiwana is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Laurentiis, Michelino De, Xin Hu, Marina Elena Cazzaniga, et al.. (2025). 489MO Patient-reported outcomes (PROs) with vepdegestrant (VEP) vs fulvestrant (FUL) in patients (pts) with estrogen receptor (ER) 1 gene mutated (ESR1m) ER+/human epidermal growth factor receptor 2 (HER2) : Advanced breast cancer (aBC) in the phase 3 VERITAC-2 trial. Annals of Oncology. 36. S380–S381. 1 indexed citations

2.

DeMuro, Carla, et al.. (2022). Patient experiences with patient-reported outcome measures in metastatic breast cancer trials: qualitative interviews. Journal of Patient-Reported Outcomes. 6(1). 60–60. 2 indexed citations

3.

Cameron, David, et al.. (2022). EE361 Cost-Effectiveness Analysis of Ribociclib Versus Abemaciclib in the First-Line (1L) Treatment of Postmenopausal Women With HR+/HER2- Advanced Breast Cancer (ABC). Value in Health. 25(12). S126–S126. 2 indexed citations

4.

Turner, Stuart, Stephen Chia, Hemanth Kanakamedala, et al.. (2021). Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, PIK3CA-Mutated Breast Cancer. The Oncologist. 26(7). e1133–e1142. 23 indexed citations

5.

Jérusalem, Guy, Thomas E. Delea, Michelino De Laurentiis, et al.. (2021). Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial. Clinical Breast Cancer. 22(4). 326–335. 4 indexed citations

6.

Thabane, Marroon, et al.. (2021). Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective. PharmacoEconomics. 39(7). 853–867. 3 indexed citations

7.

Fasching, Peter A., Aditya Bardia, Arnd Nusch, et al.. (2021). 91O Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2, -3, and -7 trials: Additional results and key subgroup findings. Annals of Oncology. 32. S60–S61. 1 indexed citations

8.

Chandiwana, David, et al.. (2021). PCN45 Analysis of Societal Costs Due to Work Productivity Loss and Activity Impairment from the Monaleesa-7 Trial of Ribociclib + Endocrine Therapy (ET) in Premenopausal Women with HR+/HER2– Advanced Breast Cancer (ABC) in Brazil. Value in Health. 24. S27–S27.

9.

Fasching, Peter A., J. Thaddeus Beck, Arlene Chan, et al.. (2020). Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. The Breast. 54. 148–154. 27 indexed citations

10.

Thabane, Marroon, et al.. (2020). PCN128 COST-EFFECTIVENESS OF RIBOCILIB PLUS FULVESTRANT (R+F) VS FULVESTRANT (FUL) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE. Value in Health. 23. S45–S45.

11.

Thabane, Marroon, et al.. (2020). PCN87 COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE. Value in Health. 23. S39–S39.

12.

Turner, Simon, Stephen Chia, Hemanth Kanakamedala, et al.. (2020). 309P Real-world effectiveness of alpelisib (ALP) + fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2–) PIK3CA-mutated (Mut) advanced breast cancer (ABC). Annals of Oncology. 31. S366–S366. 1 indexed citations

13.

Jérusalem, Guy, Thomas E. Delea, M. Martín Jiménez, et al.. (2020). 142P Quality-adjusted survival with ribociclib plus fulvestrant (R+F) versus placebo plus fulvestrant (P+F) in postmenopausal women (PMW) HR+/HER2- advanced breast cancer (ABC) based on the MONALEESA-3 trial. Annals of Oncology. 31. S66–S66. 2 indexed citations

14.

Ciruelos, Eva, et al.. (2020). 163P Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib + fulvestrant vs everolimus + exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC). Annals of Oncology. 31. S74–S74. 2 indexed citations

15.

Patterson‐Lomba, Oscar, Anand A. Dalal, Rajeev Ayyagari, et al.. (2019). Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2− breast cancer. The Breast Journal. 25(5). 880–888. 3 indexed citations

16.

Suri, Gaurav, David Chandiwana, Adam Lee, & Rohit Mistry. (2019). Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom. Journal of health economics and outcomes research. 20–31. 1 indexed citations

17.

Suri, Gaurav, David Chandiwana, Adam Lee, & Rohit Mistry. (2019). Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom. Journal of health economics and outcomes research. 6(2). 20–31. 12 indexed citations

18.

Forsythe, Anna, et al.. (2018). Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer. Breast Cancer Targets and Therapy. Volume 10. 69–78. 12 indexed citations

19.

Verma, Sunil, Joyce O’Shaughnessy, Howard A. Burris, et al.. (2017). Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.. Journal of Clinical Oncology. 35(15_suppl). 1020–1020. 9 indexed citations

20.

Swinburn, Paul, et al.. (2012). Elicitation of health state utilities in neuroendocrine tumours. Journal of Medical Economics. 15(4). 681–687. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact